In the Phase 2 IZALCO study, we evaluated efficacy, patient preference, safety and pharmacokinetics for isatuximab administered SC by an innovative on-body injector (OBI) or manual injection, plus ...

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Barriers and facilitators to seeking care for the initial diagnosis of melanoma in an urban safety-net hospital. Time Impact on time related to treatment, travel, personal, work or social activities ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct strengths and limitations. IV administration offers established dosing precision, ...

Credit: AstraZeneca. The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.

The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...

Sanofi gets approval for Sarclisa subcutaneous formulation in Japan: Paris Monday, June 22, 2026, 13:00 Hrs [IST] The Ministry of Health, Labour and Welfare in Japan has granted a ...

Ninety-one percent coverage parity was observed across seven SC/IV oncology products within 17 large U.S. commercial plans, ...